maintain hold follow result mark strong jan/feb core
trend acceler volum declin march tie
expect nt headwind persist outbreak highlight key role testing/th
lab industri play influenc healthcar decision-mak view scale
sophist provid well posit addit see a/shar gain
opportun view reimburs backdrop grow benign
liquid key view high qualiti scale provid well
posit long-term maintain hold pt bump
upbeat long-term outlook diagnost lab industri
outbreak creat meaning near-term volum headwind
think pandem also highlight critic role lab
test healthcar decision-mak also think outbreak underscor
leverage/benefit scale sophist provid quest
evidenc compani abil significantli ramp capacity/test
impress timefram roll-out new test offer maintain suppli chain
continu market reopen think compani signific scale/
capac remain key differenti mass test demand increas
think strong it/data analyt import potenti track need aris
final healthcar system return normal state time
expect ongoing/potenti acceler flight quality/valu would
expect payors/providers/pati increasingli look align scale high
qualiti well capit partner think acceler growth
opportun across host area
long-term outlook pretti solid volum impact
april stark declin includ covid test
tie shelter-at-home/meaning drop healthcar consumpt trend
look stabil expect gradual recoveri market begin
reopen see potenti opportun acceler posit
test impact molecular serolog addit test launch/capac
come on-lin compani current molecular capac
test per day complement roll antibody/serolog
test nationwid capac expect ramp tests/day mid-
may serolog reimburs rate current unknown on-going
effect manag suppli chain key expect demand
strong market re-open busi look manag risk
employe test compani combin molecular like ramp
tr target
model review figur
reflect actual
adjust non-control interest equiti
earn jv
serolog capac tests/day repres almost half normal day test volum
think becom increas tailwind help off-set portion volum headwind
current market disrupt final healthcar system return normal state
expect emerg even stronger strateg posit expect acceler
shift toward high qualiti scale liquid provid see acceler share gain/m a/partn
opportun time
begin break liquidity/financi flexibl increasingli critic given current
environ taken sever step improv liquid profile/prepar potenti futur
liquid need compani avail revolv capac cash
hand manag taken step address certain financi coven event
long-term disruption/impact addit on-going invigor program compani also
taken increment cost-control measur includ pay reduct senior executives/
board/salari employe suspens contributions/def comp plan year-
end reduc hours/overtim elimin contract labor approv furlough employe
workforc indic interest/hav lesser work load also remain encourag
high level collabor diagnost lab sector/feder govern industri
reimburs pressur on-going overhang view recent reimburs
increas molecular test step taken care act suspend pama
cut delay next round data collect encourag data point final
medicar sequestr suspens provid modest benefit quest receiv
initi tranch provid
detail april trend long-term thought compani saw solid result
january/februari revenu yoy organ organ volum growth
ex-leap year weather total volum expand oper margin impact
result sharp volum declin march volum yoy last
two week month net revenu tie declin requisit volum
revenu per req vs strhe coupl lower margin
volum headwind/high fix cost model drove adjust ep cffo
respect compani complet share repurchas
april seen volum stabil rang inclus benefit
test would like gener loss volum remain level
would expect may/jun result like improv current level benefit on-going lift
state stay home mandat continu expans capacity/demand molecular serolog
especi assum reason reimburs rate test remain construct
long-term posit industry/dgx expect near-term disrupt persist return
normal healthcar consumpt take time maintain hold rate model
review bump pt reflect optim around longer term posit
page
servic
revenu
revenu
amort intang
revenu
equiti earn jv net tax
page
base teterboro nj lead provid diagnost test inform
relat servic compani offer patient physician access diagnost laboratori servic
nation network region laboratori patient servic center addit
rapid respons laboratori grow retail footprint compani also offer esoter test
test clinic trial
clinic lab remain integr part healthcar deliveri model diagnost test critic
compon treatment decis process continu like market view
well posit given scale like share gain acceler grow access difficult
reimburs environ industri pressur grow patient pay sluggish core
volum unlik meaning abat near-term view risk/reward balanc
valuat risk
price target base trade adjust ep premium
current multipl view appropri upsid risk rate price target upsid
includ acceler volum growth improv price potenti accret downsid
risk includ deceler volum wors covid impact anticp increas denial/pati
concess stronger anticip reimburs headwind
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
